| __timestamp | Eli Lilly and Company | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 20140000 |
| Thursday, January 1, 2015 | 6533000000 | 37173000 |
| Friday, January 1, 2016 | 6452000000 | 48616000 |
| Sunday, January 1, 2017 | 6588100000 | 108488000 |
| Monday, January 1, 2018 | 5975100000 | 244622000 |
| Tuesday, January 1, 2019 | 6213800000 | 287000000 |
| Wednesday, January 1, 2020 | 6121200000 | 354000000 |
| Friday, January 1, 2021 | 6431600000 | 186000000 |
| Saturday, January 1, 2022 | 6440400000 | 151000000 |
| Sunday, January 1, 2023 | 6941200000 | 232600000 |
| Monday, January 1, 2024 | 8593800000 | 267474000 |
Igniting the spark of knowledge
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Eli Lilly and Company, a stalwart in the sector, has consistently demonstrated robust financial management. From 2014 to 2023, their SG&A expenses have shown a steady trend, peaking in 2023 with a 5% increase from the previous year. In contrast, Ionis Pharmaceuticals, Inc., a smaller player, has experienced more volatility. Their expenses surged by over 1,600% from 2014 to 2020, reflecting their aggressive growth strategy. However, recent years have seen a decline, indicating a shift towards more sustainable operations. This comparison highlights the diverse strategies within the industry, where established giants and emerging innovators navigate financial challenges differently.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Incyte Corporation
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing Innovation Spending: Eli Lilly and Company and Ionis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ionis Pharmaceuticals, Inc. Trends and Insights
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Ionis Pharmaceuticals, Inc. and MorphoSys AG
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.